Insider Buying: Celldex Therapeutics, Inc. (NASDAQ:CLDX) CEO Buys 11,500 Shares of Stock

Celldex Therapeutics, Inc. (NASDAQ:CLDX) CEO Anthony S. Marucci purchased 11,500 shares of the business’s stock in a transaction dated Monday, November 11th. The stock was bought at an average price of $26.82 per share, with a total value of $308,430.00. Following the acquisition, the chief executive officer now directly owns 40,284 shares in the company, valued at approximately $1,080,416.88. This represents a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Celldex Therapeutics Stock Up 4.5 %

Shares of CLDX traded up $1.17 during mid-day trading on Tuesday, hitting $27.38. The company had a trading volume of 112,923 shares, compared to its average volume of 869,602. The business’s 50-day simple moving average is $33.29 and its 200-day simple moving average is $35.72. Celldex Therapeutics, Inc. has a 1-year low of $24.43 and a 1-year high of $53.18. The stock has a market cap of $1.82 billion, a PE ratio of -10.20 and a beta of 1.60.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Arizona State Retirement System lifted its position in Celldex Therapeutics by 2.0% during the second quarter. Arizona State Retirement System now owns 16,231 shares of the biopharmaceutical company’s stock valued at $601,000 after buying an additional 325 shares in the last quarter. KBC Group NV lifted its position in shares of Celldex Therapeutics by 31.2% during the third quarter. KBC Group NV now owns 2,081 shares of the biopharmaceutical company’s stock worth $71,000 after purchasing an additional 495 shares in the last quarter. Los Angeles Capital Management LLC lifted its position in shares of Celldex Therapeutics by 9.5% during the second quarter. Los Angeles Capital Management LLC now owns 7,371 shares of the biopharmaceutical company’s stock worth $273,000 after purchasing an additional 638 shares in the last quarter. CANADA LIFE ASSURANCE Co lifted its position in shares of Celldex Therapeutics by 26.4% during the first quarter. CANADA LIFE ASSURANCE Co now owns 4,570 shares of the biopharmaceutical company’s stock worth $192,000 after purchasing an additional 955 shares in the last quarter. Finally, AQR Capital Management LLC lifted its position in shares of Celldex Therapeutics by 23.7% during the second quarter. AQR Capital Management LLC now owns 7,857 shares of the biopharmaceutical company’s stock worth $291,000 after purchasing an additional 1,504 shares in the last quarter.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on CLDX shares. Citigroup started coverage on shares of Celldex Therapeutics in a report on Monday, October 7th. They issued a “buy” rating and a $70.00 price target for the company. HC Wainwright reiterated a “buy” rating and issued a $80.00 price target on shares of Celldex Therapeutics in a report on Thursday, November 7th. Wells Fargo & Company upgraded shares of Celldex Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Thursday, September 26th. Wolfe Research downgraded shares of Celldex Therapeutics from an “outperform” rating to a “peer perform” rating in a report on Friday, September 27th. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $67.00 target price on shares of Celldex Therapeutics in a report on Monday, September 16th. Two research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Celldex Therapeutics has an average rating of “Moderate Buy” and an average price target of $62.25.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.